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1. Introduction1
Progressive cerebral infarction refers to after the onset of the 
symptoms of slightly neurological impairment, but showed 
increase in a progressive way. The progression can extended 
up to 48 h, until the emergence of serious defect of nervous 
function of acute ischemic stroke, which accounted 26−43% 
from total cerebral infarction [1]. The mortality rate and dis-
ability rate is higher, and the conventional treatment effect 
was not ideal. In this paper, discussion was done on the ap-
plication of urinary kallidinogenase in acute progressive ce-
rebral infarction treatment. The domestic class I new drug, 
urinary kallidinogenase, namely the urinary kinin original 
enzyme, which able to induce selective dilation in cerebral 
arterioles, and promote formation of neovascularization of 
ischemic area. 52 patients with progressive cerebral infarc-
tion patients from department of Neurology in our hospital 
which hospitalized since February 2010 to February 2013 
achieved certain curative effect in the treatment application 
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of urinary kallidinogenase. 
2. Materials and methods
2.1. General information
104 patients with progressive cerebral infarction were ran-
domly divided into control group and treatment group 
with 52 cases in each group. The control group consist of 
male 34 cases and female 18 cases, aged 23−73, and time 
interval between drug administration and disease onset 
time was less than or equal to 48 hours. There were 32 
cases of hypertension, 16 cases of hyperlipidemia, 15 cases 
of diabetes, 3 cases of atrial fibrillation, 2 cases of transient 
ischemic attack (TIA), 27 cases of smoking or/and wine 
addiction. In 52 cases of treatment group, 35 cases were 
male and 17 were female, aged from 31−80, and time in-
terval between drug administration and disease onset time 
was less than or equal to 48 hours. There were 35 cases of 
hypertension, 17 cases of hyperlipidemia, 16 cases of dia-
betes, 4 cases of atrial fibrillation, 5 cases of TIA history, 
25 cases of smoking or/and wine addiction. There was no 
significant difference in gender, age, past history, treatment 
of neurological function defect score (NIHSS) in the two 
groups (p > 0.05). There was no significant difference be-
tween the two groups (p > 0.05).
2.2. Inclusion criteria
The onset within 48 hours, and in accordance with 
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through 1995 the 4th National Conference on cerebrovas-
cular disease diagnostic criteria [2]; (1) The age is more 
than or equal to 18 years of age, (2) NIHSS score of 4 to 20; 
(3) Confirmed by cranial CT and/or MRI 2−3, and exclu-
sion of hemorrhagic infarction; (4) Without hemorrhage 
or bleeding tendency within the last 1 month; (5) Does not 
on vascular angiotensin converting enzyme inhibitor class 
of drugs within 24 hours; (6) Signed a written informed 
consent. Exclusion criteria: (1) Cerebral hemorrhage and 
other bleeding tendency, brain tumor, brain contusion and 
laceration of brain organic disease; (2) Combined cardiac 
insufficiency; (3) Chronic liver disease which cause ALT 
increased (1.5 times greater than normal); (4) Serum crea-
tinine increased (1.5 times greater than normal); (5) Age 
> 85 years old; (6) Allergic constitution; (7) Dementia and 
psychosis.
2.3. Control group
The basic drugs were: Bayaspirin 300 mg/d for 7 d, then 
reduce to 100 mg/d, Atorvastation 20 mg, Ginkgo biloba 
extract 20 mL + 0.9% normal saline, 250 mL intravenous 
infusion once per day. Treatment group: Basic Medicine 
and give 0.15 PNA urinary kallidinogenase with 0.9% nor-
mal saline 100 mL intravenous drip for 1 h, 1 times/day, 
treatment for 14 days. Patients with primary disease in 
both groups was treated with respective symptomatic ther-
apy, such as adjusting blood sugar, control blood pressure 
and other conventional treatment such as rehabilitation 
therapy. During the treatment period ACEI drugs admin-
istration was restricted. 
2.4. Efficacy evaluation
NIHSS score of patients were recorded before and after 
14 d of drugs administration, and determine according 
increase or decrease of the score. Healing: functional de-
fect score decreased from 91% to 100%; Significant prog-
ress: functional defect score decreased from 46% to 90%; 
Progress: functional defect score decreased from 18% 
to 45%; Invalid: functional defect score was reduced by 
17%. Total effective rate = (basic recovery + significant 
progress + progress) case number/total number of cases 
× 100%. Telephone follow-up at 3 months, to estimate BI 
score. Blood routine, liver, renal function, glucose and 
blood lipid were detected before and after treatment, 
careful observation and detailed record of adverse reac-
tions.
2.5. Statistical methods
Using SPSS 13.0 statistical software, measurement data ( x  
± s); between the two groups compared with t test; count 
data with x2 test.
3. Results
3.1. Comparison of neural function defect score
The score of neurological function in the treatment group 
before treatment was (7.91 ± 0.89), and the neurologi-
cal function score after treatment was (3.82 ± 0.81). The 
score of neurological function in the control group before 
treatment was (7.78 ± 1.02), and the neurological func-
tion score after treatment was (5.76 ± 0.43). Two groups 
of patients before treatment, t test value for neurological 
function score was 1.236541, and p value was 0.985612, the 
difference was not statistically significant (p > 0.05); after 
treatment, t test value for both neurological function score 
was 12.956587, and p value was 0.000125, two groups were 
significantly different (p < 0.05). Specific results are shown 
in Table 1.
Table 1. NIHSS score of two groups of patients after treat-
ment.
Group n Before treatment After treatment
Treatment group 52 7.91 ± 0.89 3.82 ± 0.81
Control group 52 7.78 ±1.02 5.76 ± 0.43
t - 1.236541 12.956587
p - 0.985612 0.000125
3.2. Comparison of the two groups of patients
Comparison of two groups of patients in the treatment: 
treatment group 5 cases of healing, 18 cases of significant 
progress, 20 cases of progress, unchanged in 7 cases, and 2 
cases of death. While, for the control group, there were 2 
cases of healing, 10 cases of significant progress, progress 
in 17 cases, unchanged in 3 cases and 20 cases of death. 
The effective rate of treatment group was significantly 
higher than that of control group (p < 0.01). There were 
significant differences in total effective rate between the 
two groups (p < 0.05) (Table 2).
3.3. Laboratory index
Liver and kidney function, blood routine, urine routine, 
PT, TT, APTT before and after treatment and between the 
two groups had no obvious changes.
Table 2. Comparison of clinical efficacy between the two groups (%).
Group n Basic healing Significant 
progress
Progress No change
Death 
deterioration
Explicit 
efficiency
Total 
efficiency
Treatment group 52 5 18 20 7 2 44.2% 82.6%
Control group 52 2 10 20 17 3 23.1% 61.5%
x2 - 1.37849 3.12782 0.00 5.41667 0.21010 5.21077 5.78575
p - 0.240357 0.07697 0.00 0.01994 0.64669 0.02245 0.01616
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3.4. Follow up results
Three month after discharged from hospital, followed up 
was done by telephone, which control group and treatment 
group were followed up 40 and 43 cases, respectively. The 
result was analyzed with B1 and MRS to measure the daily 
life ability of patients. If B1 > 95 points, basic life can be in-
dependent; whereas if B1 < 95 points, basic life cannot be 
independent. There was no significant difference in NHISS 
score between the two groups, and the follow-up results 
showed that the x2 test showed that the two groups had 
significant difference after three month (p < 0.05).
Table 3. B1 values of 3 months after follow-up.
Group n     B1 index
B1 > 95                B1 < 95
Treatment group 43   31                        12
Control group 40   19                        21
4. Discussion
At present, the pathogenesis of progressive stroke was 
cause by the formation of primary thrombus, subsequently 
resulted disappearance of collateral circulation, and the 
changes of blood coagulation factors which is caused by 
the blockage of collateral vessels. Therefore, the establish-
ment of collateral circulation can be improved as soon as 
possible after the onset of the disease, and it can inhibit the 
formation of thrombus, and save the function of the cells 
in the area of the ischemic and the half dark zone is the key 
to the treatment [3]. Urinary kallidinogenase is a new drug 
developed in recent years, which is extracted from the 
urine of healthy men. The pharmacodynamic experiment 
shows that in a certain dose of urinary kallidinogenase 
cause selective dilation of the ischemic area small arteries, 
increase cerebral ischemia tissue blood flow, improve the 
cerebral microcirculation, increase the red cell deforma-
tion and the oxygen dissociation ability, promote the or-
ganization’s use of glucose, inhibit platelet aggregation and 
blood coagulation [4,5]. In addition, in clinical practice, 
effect of urinary kallidinogenase on blood pressure was be-
ing concern. Research shows that urinary kallidinogenase 
and ACEI class of antihypertensive drugs have synergistic 
effect, co-administration shown significant effect to blood 
pressure. The mechanism as follows: angiotensin con-
verting enzyme induced peptidase II, rapidly hydrolyzes 
bradykinin and angiotensin converting enzyme inhibitor 
(ACEI) can increase blood concentrations of bradykinin 
and enhanced bradykinin antihypertensive effect [6], so in 
clinical practice should avoid the combination of the two.
The authors observed, acute cerebral infarction progress 
period the use of urinary kallidinogenase, NIHSS score 
was significantly decreased after treatment, and compared 
with the control group, it reduce significantly (p < 0.05). 
From the clinical efficacy, the treatment group achieved 
44.2%, which higher than the control group, there was 
significant difference (p < 0.05), indicating that the drug 
having rapid onset of action. Besides, side effect of urinary 
kallidinogenase was low and mild, generally disappear of 
symptoms after slowing down the administration rate, and 
so far no adverse reaction was observed. Strict monitor-
ing of blood pressure did not fall. There was no significant 
difference between the treatment group and the control 
group. So for no thrombolysis syndrome cases, because the 
current lacking of effective method in the treatment, time-
ly use of urinary kallidinogenase in treatment of acute pro-
gressive cerebral infarction is a safe and effective treatment. 
The long-term effects of the follow-up were observed, and 
the clinical effect was further evaluated.
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